For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
Ipamorelin is a selective GHS-R1a (ghrelin receptor) agonist and the first GH secretagogue documented not to stimulate ACTH or cortisol even at 200x therapeutic doses. Its only completed published human RCT -- a Phase 2 trial for postoperative ileus -- failed its primary endpoint (P=0.15), ending the pharmaceutical development program. All body composition and anti-aging claims are extrapolations from GH biology with no direct human trial evidence.
Ipamorelin has never been FDA-approved for any therapeutic indication and has no approved indications anywhere in the world. Its only completed published human clinical trial -- a Phase 2 RCT for postoperative ileus -- failed to meet its primary endpoint (P=0.15), which effectively ended the pharmaceutical development program originally led by Novo Nordisk and later Helsinn Therapeutics.
The regulatory timeline is nuanced. In late 2023, the FDA placed ipamorelin on its Category 2 bulk drug substances list, prohibiting 503A compounding pharmacies from preparing it. In September 2024, the FDA removed ipamorelin from the Category 2 list and referred it to the Pharmacy Compounding Advisory Committee for evaluation -- representing a procedural acknowledgment, not a safety clearance. As of March 2026, ipamorelin is under PACC review, not approved, and banned by WADA for athletes.
The FDA's Category 2 classification was driven primarily by the lack of human clinical data and insufficient safety information, manufacturing quality concerns with unnatural amino acid-containing peptides, and a reported serious adverse event (death) during an IV-route gastric motility study with unestablished causality. The IV route involved is not standard clinical practice.
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively agonizes the ghrelin/growth hormone secretagogue receptor (GHS-R1a) pathway to stimulate growth hormone release from the pituitary gland. It was identified within a series of compounds lacking the central dipeptide Ala-Trp of growth hormone-releasing peptide (GHRP)-1. In vitro, ipamorelin released GH from primary rat pituitary cells with a potency and efficacy similar to GHRP-6.
The critical discovery that defined ipamorelin's scientific identity was its uniquely selective safety profile compared to other GH secretagogues of the same class. Administration of both GHRP-6 and GHRP-2 resulted in increased plasma levels of ACTH and cortisol. Ipamorelin did not release ACTH or cortisol in levels significantly different from those observed following GHRH stimulation -- even at doses more than 200-fold higher than the ED50 for GH release. Ipamorelin is the first GHRP-receptor agonist with a selectivity for GH release similar to that displayed by GHRH.
A critical mechanistic distinction: ipamorelin acts via GHS-R1a (the ghrelin receptor), not GHRH-R. It is a ghrelin mimetic, not a GHRH analog. This is a mechanistically distinct pathway to GH stimulation with different tissue distributions, different off-target profiles, and different synergistic potential. This means ipamorelin and sermorelin or tesamorelin can be combined (the CJC-1295/ipamorelin stack uses a GHRH analog plus a ghrelin mimetic for synergistic GH stimulation via complementary receptor pathways) but they are not mechanistically interchangeable.
Ipamorelin is a selective agonist of the ghrelin/GHS receptor pathway (GHS-R1a). By mimicking ghrelin, ipamorelin selectively binds the same GHSR-1a receptor as GHRP-2, GHRP-6, and ibutamoren. This interaction with GHSR-1a leads to GH release from the pituitary gland, which can influence anabolic processes including appetite regulation, fat processing, and overall energy usage. The GHSR-1a receptor is also present in regions outside the brain including the gastrointestinal tract.
The defining mechanism is selectivity: ipamorelin did not release ACTH or cortisol in levels significantly different from those observed following GHRH stimulation, even at doses more than 200-fold higher than the ED50 for GH release. All prior GHRPs (GHRP-2, GHRP-6) elevated ACTH and cortisol alongside GH, which is a significant physiological liability for chronic use. This selectivity, if translated to humans with the same profile, would represent a meaningful safety improvement over earlier GHRPs for chronic use applications.
The GHSR-1a receptor in the GI tract is the mechanistic basis for the postoperative ileus application -- ghrelin and ghrelin mimetics are prokinetic through peripheral gut receptors. Somatostatin still modulates the downstream GH axis as a physiological safety ceiling. PK/PD data established dose-proportional kinetics, a short terminal half-life of 2 hours, clearance of 0.078 L/h/kg, and volume of distribution at steady-state of 0.22 L/kg, with a single GH pulse peaking at approximately 40 minutes post-dose and returning to baseline within 2 to 3 hours.
One hundred and seventeen patients were enrolled, of whom 114 composed the safety and modified intent-to-treat populations. Overall incidence of any treatment-emergent adverse events was 87.5% in the ipamorelin group and 94.8% in the placebo group. Median time to first tolerated meal was 25.3 and 32.6 hours in the ipamorelin and placebo groups, respectively (P=0.15). There were no significant differences between ipamorelin and placebo in the key and secondary efficacy analyses.
Ipamorelin failed its Phase 2 clinical trial for postoperative ileus, with the trial discontinued due to lack of efficacy. A second Phase 2 RCT was registered (NCT01280344, Helsinn Therapeutics) but its results were never published -- a significant gap in the evidence record.
The postoperative ileus application is ipamorelin's only completed published human RCT and it produced a negative result on its primary endpoint. The mechanistic rationale (GHS-R1a agonism in GI tract smooth muscle producing prokinetic effect) remains biologically coherent. The failure may reflect trial design issues (heterogeneous patient population, IV route in a POI context, suboptimal dosing). However, a failed Phase 2 primary endpoint in the only published human trial represents the lowest category of clinical efficacy evidence. This single failed trial forms the entire empirical foundation upon which all other claims about ipamorelin in humans must be evaluated.
The PK parameters showed dose-proportionality, with a short terminal half-life of 2 hours, clearance of 0.078 L/h/kg, and volume of distribution at steady-state of 0.22 L/kg. The time course of GH stimulation by ipamorelin showed a single episode of GH release with a peak at 0.67 hours and an exponential decline to negligible GH concentration at all doses. Ipamorelin induces the release of GH at all dose levels with the concentration required for half-maximal GH stimulation of 214 nmol/L and a maximal GH production rate of 694 mIU/L/h. The inter-individual variability of the PD parameters was larger than that of the PK parameters.
This study established ipamorelin's dose-proportional kinetics, characterized a clean single-pulse GH release pattern (peak at approximately 40 minutes post-dose, return to baseline within 2 to 3 hours), and confirmed dose-dependent GH stimulation across a 33-fold dose range.
This is ipamorelin's most methodologically rigorous human study and confirms that the mechanism works in humans at the GH stimulation level. However, PK/PD modeling of a single GH pulse does not constitute evidence of clinical benefit. The large inter-individual variability in PD parameters (GH response magnitude varies substantially person-to-person) is a clinically important finding suggesting responder heterogeneity that would need to be addressed in any therapeutic application.
The maximum tetanic tension was increased significantly, and the periosteal bone formation rate increased four-fold in animals injected with glucocorticoid and ipamorelin in combination, compared with the group injected with glucocorticoid alone. The decrease in muscle strength and bone formation found in glucocorticoid-injected rats was counteracted by simultaneous administration of ipamorelin.
All treatments (ipamorelin, GHRP-6, GH, vs. vehicle) increased body weight and total tibial and vertebral bone mineral content measured by DXA compared with vehicle-treated controls. The increase in cortical BMC was due to an increased cross-sectional bone area, whereas the cortical volumetric BMD was unchanged.
The preclinical bone data for ipamorelin is among the most interesting findings in the compound's literature, generating a high-value clinical hypothesis with no human follow-up. The four-fold increase in periosteal bone formation rate in glucocorticoid-treated rats addresses glucocorticoid-induced osteoporosis (GIOP), which affects up to 50% of patients on long-term corticosteroids and causes fractures in 30 to 50% of those patients. Despite this compelling preclinical rationale spanning over two decades, no human trial of ipamorelin for GIOP or bone density has ever been conducted.
Over 9 weeks, body weight in GH-deficient mice increased by 15.3% in those treated with ipamorelin compared to 95.5% in those treated with GH. There were no changes in the relative weight of dissected organs with ipamorelin while GH led to increased liver weight. This suggests that patients treated with ipamorelin may not experience the same organomegaly as that seen in patients treated with GH itself.
The absence of organomegaly -- particularly liver enlargement -- with ipamorelin compared to direct GH is a notable safety differentiator. GH-induced organomegaly is one of the most clinically concerning long-term adverse effects of supraphysiological GH exposure.
There are zero published prospective human trials examining ipamorelin's effects on body composition -- lean mass, fat mass, visceral fat, or metabolic parameters -- in any population. All body composition claims for ipamorelin in humans are extrapolations from animal data and mechanistic reasoning via GH/IGF-1 biology. The absence of organomegaly with ipamorelin versus rhGH is directionally reassuring from animal models but not translatable to human body composition endpoints.
The GHS-R1a agonists anamorelin and ipamorelin inhibit cisplatin-induced weight loss in ferrets; anamorelin also exhibits anti-emetic effects via a central mechanism.
The cancer cachexia application for ipamorelin is best understood through its structural relationship to anamorelin -- an oral GHS-R1a agonist approved in Japan for cancer cachexia (brand name Adlumiz). Anamorelin and ipamorelin share the same receptor mechanism (GHS-R1a agonism) and the same downstream GH/IGF-1/appetite effects. Anamorelin's success in Japanese Phase 3 trials validates the GHS-R1a agonist approach for this indication in principle. However, ipamorelin itself has never been studied in cancer cachexia patients.
Very Low for ipamorelin specifically. The mechanistic premise is validated by anamorelin's regulatory approval in Japan, but ipamorelin itself has no human cachexia data. Oral bioavailability was likely crucial for cancer patient compliance, which ipamorelin (injectable only) cannot match. This may be one reason ipamorelin was not developed further in oncology.
Ipamorelin dose-dependently increased longitudinal bone growth rate from 42 micrometers/day in the vehicle group to 44, 50, and 52 micrometers/day in the treatment groups (P<0.0001). There was also a pronounced and dose-dependent effect on body weight gain. The plasma GH response to a provocative dose of ipamorelin was marginally reduced (P<0.03) after ipamorelin treatment, but unchanged after GHRH.
The marginal reduction in subsequent pituitary GH response to provocative ipamorelin dosing (but not to GHRH) suggests a degree of receptor-level desensitization with repeated ipamorelin exposure that does not occur at the GHRH receptor level. This is mechanistically important: ipamorelin may carry slightly more tachyphylaxis risk than sermorelin at the GHS-R1a receptor level, though no long-term human desensitization studies exist.
Low. Purely preclinical data in a rat growth model. No human pediatric growth studies were conducted with ipamorelin. This application was rendered moot by the failure of the POI clinical program, which ended pharmaceutical company investment before pediatric trials could be initiated. The GHS-R1a desensitization signal is mechanistically noteworthy for chronic use protocols.
Typically stacked with CJC-1295. Standard protocol: 200-300mcg before bed or post-workout.
Ipamorelin has no validated human dosing protocol for any application other than the failed IV POI trial. All SubQ dosing used in research and compounding practice is extrapolated from preclinical data and mechanistic reasoning. Research-grade quality standards: HPLC purity 98% or above, mass spec confirmation of pentapeptide sequence, endotoxin below 1 EU/mg for injectable use. Compounds containing unnatural amino acids (Aib, D-2-Nal, D-Phe) present specific characterization and purity challenges that the FDA cited as a manufacturing concern for compounded preparations.
Ipamorelin vs. sermorelin and tesamorelin (GH secretagogue comparison): All three stimulate GH release via different receptors and with different evidence bases. Tesamorelin is FDA-approved with Phase 3 data. Sermorelin was formerly FDA-approved with a well-characterized safety record and human aging data. Ipamorelin has a failed Phase 2 POI trial as its only published human efficacy data, with all other applications resting on preclinical evidence and mechanistic extrapolation.
Ipamorelin's key mechanistic differentiator is ACTH/cortisol selectivity at GHS-R1a -- no HPA stress axis stimulation even at 200x therapeutic doses. This advantage is real. But unlike sermorelin's physiological ceiling via somatostatin feedback, ipamorelin's selectivity is receptor-level rather than axis-level. The practical clinical significance of this distinction has never been tested in an adequately powered human trial.
Ipamorelin vs. BPC-157 (comparing compounds without human efficacy data): BPC-157 also lacks human trial data for its primary applications, but has never been through a failed Phase 2 trial. Ipamorelin's situation is specifically that its primary development indication was formally tested and failed -- not merely an absence of evidence, but evidence of absence for the application it was designed for.
Ipamorelin's human safety data is limited to two studies: the Beck et al. 2014 Phase 2 trial at 0.03 mg/kg IV twice daily for up to 7 days (n=114), and the Gobburu 1999 PK/PD study in 40 healthy males across a 33-fold dose range. In both studies, no concerning safety signals were documented. Adverse event rates in the Beck POI trial were actually numerically lower in the ipamorelin group (87.5%) than placebo (94.8%), though this reflects the underlying surgical population rather than drug-specific effects.
A serious adverse event including a death was noted during an IV gastric motility study. Causality was not established, and the IV route involved is not standard clinical practice for the compounding-era applications. The FDA cited this in its Category 2 documentation.
Theoretical safety concerns from the mechanism include: GHS-R1a is expressed in cardiac tissue, and ghrelin has documented positive chronotropic effects, making tachycardia at higher doses mechanistically plausible; IGF-1 elevation carries the same theoretical cancer concern as all GH-axis compounds; glucose counter-regulation is less pronounced than direct rhGH but still present; no carcinogenicity studies have been conducted. The absence of organomegaly with ipamorelin versus direct rhGH (observed in murine models) is a potentially favorable differentiator. Manufacturing quality concerns with unnatural amino acid-containing peptides are a legitimate regulatory concern for compounded preparations.
Ipamorelin occupies the weakest evidence position among the GH secretagogue compounds reviewed. Its sole completed published human clinical trial produced a negative primary endpoint result (P=0.15), ending the pharmaceutical development program. Every clinical application currently promoted in wellness medicine -- body composition, anti-aging, sleep quality, muscle recovery -- rests entirely on mechanistic reasoning, animal data, and extrapolation from GH biology rather than any direct human evidence.
The one genuinely distinctive and scientifically important characteristic is ACTH/cortisol selectivity -- the failure to stimulate the HPA stress axis even at 200 times therapeutic doses. This selectivity, if consistent in humans as the PK/PD data suggests, would represent a meaningful safety improvement over GHRP-2 and GHRP-6 for chronic use. The fundamental problem is that no adequately powered human study has ever tested whether ipamorelin's clinical efficacy in any application justifies its use. The failure of the POI trial was not merely an absence of evidence -- it was evidence of absence for the specific application it was designed for.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use